肾纤维化：不止纤溶酶原激活物抑制剂-1这么简单。
Renal fibrosis: not just PAI-1 in the sky.
作者信息
Fogo Agnes B
机构信息
Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
出版信息
J Clin Invest. 2003 Aug;112(3):326-8. doi: 10.1172/JCI19375.
Abstract
A delicate balance exists between ECM synthesis and degradation such that interruption of the corresponding pathways results in increased plasminogen activator inhibitor-1 (PAI-1), pathological matrix accumulation, and glomerulosclerosis. A new study demonstrates that therapy with a mutant PAI-1 increases matrix turnover and reduces glomerulosclerosis by competing with endogenous PAI-1, suggesting therapeutic utility in the treatment of fibrotic renal disease.
摘要
细胞外基质（ECM）的合成与降解之间存在着微妙的平衡，因此相应途径的中断会导致纤溶酶原激活物抑制剂-1（PAI-1）增加、病理性基质积聚和肾小球硬化。一项新研究表明，用突变型PAI-1进行治疗可通过与内源性PAI-1竞争来增加基质周转并减少肾小球硬化，这表明其在治疗纤维化肾病方面具有治疗价值。
相似文献
1
Renal fibrosis: not just PAI-1 in the sky.
J Clin Invest. 2003 Aug;112(3):326-8. doi: 10.1172/JCI19375.
2
Plasminogen activator inhibitor-1 in kidney pathology (Review).
Int J Mol Med. 2013 Mar;31(3):503-10. doi: 10.3892/ijmm.2013.1234. Epub 2013 Jan 10.
3
[Modulation of aberrant extracellular matrix degradation systems by astragali radix and angelicae sinensis radix decoction (A&A) in interstitial fibrotic kidney].
Zhongguo Zhong Yao Za Zhi. 2012 Jan;37(1):79-84.
4
Aldosterone and PAI-1: implications for renal injury.
J Nephrol. 2002 May-Jun;15(3):230-5.
5
Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.
Kidney Int. 2000 Nov;58(5):1841-50. doi: 10.1111/j.1523-1755.2000.00355.x.
6
Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
Toxicol Sci. 2007 Apr;96(2):346-56. doi: 10.1093/toxsci/kfm010. Epub 2007 Jan 29.
7
Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):365-71. doi: 10.1161/01.ATV.0000152356.85791.52. Epub 2004 Dec 2.
8
Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.
Circ Res. 2004 Sep 17;95(6):637-44. doi: 10.1161/01.RES.0000141427.61023.f4. Epub 2004 Aug 5.
9
Plasminogen activator inhibitor-1 and the kidney.
Am J Physiol Renal Physiol. 2002 Aug;283(2):F209-20. doi: 10.1152/ajprenal.00032.2002.
10
Plasminogen activator inhibitor-1 and diabetic nephropathy.
Nephrology (Carlton). 2005 Oct;10 Suppl:S11-3. doi: 10.1111/j.1440-1797.2005.00449.x.
引用本文的文献
1
Synergic Renoprotective Effects of Combined ASC Therapy with RAAS Blockade in Experimental Advanced CKD.
Stem Cells Int. 2022 Mar 25;2022:5111782. doi: 10.1155/2022/5111782. eCollection 2022.
2
Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.
Nat Genet. 2019 Nov;51(11):1574-1579. doi: 10.1038/s41588-019-0519-3. Epub 2019 Nov 1.
3
FFNT25 ameliorates unilateral ureteral obstruction-induced renal fibrosis.
Ren Fail. 2019 Nov;41(1):419-426. doi: 10.1080/0886022X.2019.1612430.
4
C/EBP homologous protein (CHOP) deficiency ameliorates renal fibrosis in unilateral ureteral obstructive kidney disease.
Oncotarget. 2016 Apr 19;7(16):21900-12. doi: 10.18632/oncotarget.7870.
5
Interactions between HIF-1α and AMPK in the regulation of cellular hypoxia adaptation in chronic kidney disease.
Am J Physiol Renal Physiol. 2015 Sep 1;309(5):F414-28. doi: 10.1152/ajprenal.00463.2014. Epub 2015 Jul 1.
6
Low-molecular-weight heparin modulates vein wall fibrotic response in a plasminogen activator inhibitor 1-dependent manner.
J Vasc Surg Venous Lymphat Disord. 2014 Oct 1;2(4):441-450.e1. doi: 10.1016/j.jvsv.2014.02.004.
7
Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.
J Thromb Haemost. 2014 Aug;12(8):1353-63. doi: 10.1111/jth.12644. Epub 2014 Jul 23.
8
Ginger extract diminishes chronic fructose consumption-induced kidney injury through suppression of renal overexpression of proinflammatory cytokines in rats.
BMC Complement Altern Med. 2014 May 27;14:174. doi: 10.1186/1472-6882-14-174.
9
The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?
Fibrogenesis Tissue Repair. 2014 Mar 28;7(1):4. doi: 10.1186/1755-1536-7-4.
10
Triglycerides are independently associated with albuminuria in Taiwanese Type 2 diabetic patients.
J Endocrinol Invest. 2012 Oct;35(9):800-3. doi: 10.3275/8060. Epub 2011 Nov 8.
本文引用的文献
1
Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice.
Am J Pathol. 2003 Oct;163(4):1261-73. doi: 10.1016/s0002-9440(10)63486-4.
2
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
J Clin Invest. 2003 Aug;112(3):379-88. doi: 10.1172/JCI18038.
3
Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis.
J Clin Invest. 2002 Dec;110(12):1859-68. doi: 10.1172/JCI15045.
4
Remission of renal disease: recounting the challenge, acquiring the goal.
J Clin Invest. 2002 Dec;110(12):1753-8. doi: 10.1172/JCI17351.
5
Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy.
J Clin Invest. 2002 Nov;110(10):1525-38. doi: 10.1172/JCI16219.
6
Evidence that fibroblasts derive from epithelium during tissue fibrosis.
J Clin Invest. 2002 Aug;110(3):341-50. doi: 10.1172/JCI15518.
7
Plasminogen activator inhibitor-1 and the kidney.
Am J Physiol Renal Physiol. 2002 Aug;283(2):F209-20. doi: 10.1152/ajprenal.00032.2002.
8
The effect of endothelial cell overexpression of plasminogen activator inhibitor-1 on smooth muscle cell migration.
J Vasc Surg. 2002 Jul;36(1):164-71. doi: 10.1067/mva.2002.123687.
9
Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy.
Kidney Int. 2002 Jun;61(6):2142-8. doi: 10.1046/j.1523-1755.2002.00384.x.
10
Angiotensin as inducer of plasminogen activator inhibitor-1 and fibrosis.
Contrib Nephrol. 2001(135):161-70. doi: 10.1159/000060164.
Zotero 插件